April 5, 2019
A health ministry’s drug safety panel approved on April 2 the reclassification of a switch-OTC version of Mochida Pharmaceutical’s hyperlipidemia treatment Epadel (ethyl icosapentate), which is currently classified as a “ behind-the-counter (BTC) drug ”, as a Class 1 OTC...read more